Join a Legacy of Innovation 110 Years and Counting!
With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group's 2025 Vision to become a "Global Pharma Innovator with a Competitive Advantage in Oncology," Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases.
Under the direction of the Executive Director, Oncology Search & Evaluation, the position is responsible for managing a broad range of external activities related to building the long-term health of the internal research and development pipeline for the oncology therapeutic area. This position independently scouts and identifies potential in-licensing and co-development opportunities including academic and industrial R&D collaborations, external technology platforms, and pre-clinical and clinical stage development candidates, and leads cross-functional evaluation teams for such evaluations. Also provides technical and scientific support for evaluation of marketed products and M&A opportunities primarily in oncology and immunology. Additionally, this position works with global Cancer Enterprise R&D leadership including research lab heads, clinical therapeutic area heads and Global Brand Strategy and serves as a key opinion leader internally and maintains strong relationships with a broad network of external key opinion leaders for the oncology therapeutic area. This position solves problems with experience and seeks additional guidance for non-routine decisions.
- Pipeline Development Strategy: Helps define strategic needs at every phase and implements actional strategic plans within the oncology therapeutic area. Supports the development of in-licensing candidate wish list(s). Provides recommendations for process improvements in implementation when applicable.
- Stakeholder Interaction: Establishes and maintains a broad network of internal and external stakeholders to form valuable partnerships.
- Committee Participation: Leads cross-functional evaluation teams independently. Serves as a member of external research collaboration steering committees. Develops and manages processes and communications, as needed.
- Sourcing Opportunities: Establishes and maintains a network of external investigators and key opinion leaders. Establishes relationships with potential co-development and in-licensing partners to accelerate the identification of external opportunities. Provides expertise in the scientific assessment, therapeutic evaluation and feasibility for external in-licensing and research collaboration opportunities as part of the global scientific assessment with internal stakeholders from the US, EU and Japan. Supports the internal scientific review and feasibility process once decision is made to purse a confidential level review. Works in unison with Cancer Enterprise R&D, Commercial, CMC and Global Business Development to support the evaluation and feasibility analysis team to coordinate a full overview of in-licensing opportunities and prepare documents for submission and presentation to the Senior Licensing Committee and R&D and Corporate governance committees. Ensures the identification and engagement of a Cancer Enterprise champion for in-licensing opportunities within the evaluation team. Implements innovative sourcing strategies.
Successful candidates will be able to meet the qualifications below with or without a reasonable accommodation.
- Advanced degree PhD, DVM, or MD - is required
- 7-10 years' experience as an oncology research scientist in the pharmaceutical industry with in vitro and/or in vivo discovery research laboratory experience
- Alternatively, 5 - 7 years' experience in managing clinical research programs evaluating novel oncology or immunology treatments with demonstrated expertise in the identification and evaluation of novel therapeutic approaches
- 3-5 years' experience associated with a search and evaluation or business development capacity in the pharmaceutical industry and has led the internal process of managing the scientific/technical due diligence review of an external in-licensing candidate in oncology and/or inflammation/immunology.
- Demonstrated excellence in management of staff in a pharmaceutical R&D discipline is desirable.
- Demonstrated ability to work in a team environment and has leadership competency to take initiative and implement the project from initiation through to transfer to the transaction team.
- Subject matter expert in the oncology therapeutic area. Scientific knowledge and experience with biologics.
- A good understanding of the drug discovery and development process, CMC, intellectual property, contracts and negotiating is required. Understanding of regulatory and development standards for US, EU and ROW are desirable.
- Excellent scientific judgment and analytical skills, creativity, and independent decision-making ability. Strong involvement in decision making process for Go / No-Go decisions.
Ability to travel up to 30% of the time (international and domestic travel)
Daiichi Sankyo, Inc. is an equal opportunity/affirmative action employer. Qualified applicants will receive consideration for employment without regard to sex, gender identity, sexual orientation, race, color, religion, national origin, disability, protected veteran status, age, or any other characteristic protected by law.